M2 Pharma - Therapy Areas

Therapy Areas: Oncology

REGiMMUNE launches Phase I/II trial of RGI-2001

1 February 2012 - REGiMMUNE Corporation announced on Tuesday the launch of its Phase I/II study of the RGI-2001 compound for Graft versus Host Disease (GvHD) associated with hematopoietic stem cell transplantation.

The study will enrol some 50 bone marrow or peripheral blood stem cell trans...

You must be logged in to view the whole article.
Click here if you require signing up

Related Headlines

Myriad unveils positive results of Prolaris test analysis

Medivation, Astellas unveil promising Phase III data for MDV3100 in prostate cancer

Geron finalises patient enrolment in Phase II trial of imetelstat

MannKind seeks USD75m from sale of shares, warrants

Janssen's Zytiga fails to secure NICE recommendation

Ipsen sells Photocure's Hexvix for EUR1.3m in Q4 2011

EUSA Pharma secures rights to ASPAREC from Alize Pharma

Ligand unveils positive results of Phase II trial of Melphalan

Navidea Biopharmaceuticals gets CHMP's go-ahead to file MAA for Lymphoseek

Verastem IPO underwriters use greenshoe option in full

FDA approves changes in Novartis drug Gleevec label

REGiMMUNE launches Phase I/II trial of RGI-2001

Biomerica releases new test to detect patients at risk of developing serious side effects from thiopurine drugs

Allos seeks re-examination of CHMP opinion on FOLOTYN

biOasis to assess BT2111 in animal models of breast cancer metastasis in brain